Nikhil C Munshi Selected Research

BHQ880

11/2014	A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
7/2009	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nikhil C Munshi Research Topics

Disease

188	Multiple Myeloma 06/2022 - 02/2002
98	Neoplasms (Cancer) 01/2022 - 07/2002
11	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 10/2003
9	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2021 - 07/2004
8	Residual Neoplasm 10/2021 - 07/2013
6	Carcinogenesis 01/2021 - 02/2011
5	Lymphoma (Lymphomas) 01/2022 - 07/2006
5	Paraproteinemias (Monoclonal Gammopathy) 01/2020 - 03/2007
5	Adenocarcinoma 01/2020 - 05/2004
4	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 08/2012
4	Plasmacytoma 09/2007 - 09/2002
4	Chromosomal Instability (Chromosome Stability) 10/2003 - 07/2002
3	Infections 02/2022 - 05/2002
3	Fatigue 01/2022 - 08/2010
3	Genomic Instability 01/2021 - 01/2018
3	Monoclonal Gammopathy of Undetermined Significance 01/2018 - 10/2009
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2018 - 07/2009
3	Colonic Neoplasms (Colon Cancer) 08/2016 - 01/2014
3	Bone Diseases (Bone Disease) 01/2016 - 07/2009
3	Leukemia 01/2016 - 03/2007
3	Bone Resorption 08/2012 - 10/2007
3	Human Influenza (Influenza) 03/2011 - 06/2003
2	Disease Progression 01/2022 - 01/2016
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2021 - 07/2006
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2019 - 03/2013

Drug/Important Bio-Agent (IBA)

35	Bortezomib (Velcade)FDA Link 01/2022 - 09/2002
26	Lenalidomide (CC 5013)FDA Link 01/2022 - 12/2004
23	Pharmaceutical PreparationsIBA 06/2022 - 02/2003
21	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 02/2002
18	Proteasome InhibitorsIBA 06/2022 - 10/2002
16	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2002
14	Biological ProductsIBA 01/2020 - 07/2006
14	AntigensIBA 01/2019 - 06/2003
13	Interleukin-6 (Interleukin 6)IBA 08/2016 - 07/2002
10	CytokinesIBA 01/2017 - 07/2002
9	MicroRNAs (MicroRNA)IBA 01/2020 - 10/2010
9	Thalidomide (Thalomid)FDA Link 11/2019 - 06/2002
9	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2013 - 07/2002
8	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2003
8	Monoclonal AntibodiesIBA 01/2020 - 07/2005
8	NF-kappa B (NF-kB)IBA 04/2010 - 08/2002
7	B-Cell Maturation AntigenIBA 06/2022 - 07/2006
7	Immunomodulating AgentsIBA 11/2021 - 04/2009
6	Chimeric Antigen ReceptorsIBA 06/2022 - 01/2021
6	Biomarkers (Surrogate Marker)IBA 10/2021 - 10/2007
6	Immunoglobulin G (IgG)IBA 11/2014 - 07/2005
5	Immunoconjugates (Immunoconjugate)IBA 11/2021 - 07/2004
5	Peptides (Polypeptides)IBA 01/2019 - 06/2012
5	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 10/2003
5	Histone Deacetylase InhibitorsIBA 01/2018 - 05/2003
5	Melphalan (Alkeran)FDA LinkGeneric 01/2018 - 07/2002
4	Immunoglobulin M (IgM)IBA 11/2021 - 12/2008
4	Long Noncoding RNAIBA 01/2021 - 01/2018
4	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2021 - 05/2005
4	EnzymesIBA 08/2017 - 10/2003
4	Messenger RNA (mRNA)IBA 10/2015 - 08/2008
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2012 - 04/2003
4	perifosineIBA 04/2010 - 05/2006
4	Cytotoxins (Cytolysins)IBA 04/2009 - 07/2004
4	GlucocorticoidsIBA 12/2007 - 06/2005
4	Insulin-Like Growth Factor I (IGF-1)IBA 09/2003 - 08/2002
3	Immunoglobulins (Immunoglobulin)IBA 02/2022 - 01/2006
3	pomalidomideIBA 11/2021 - 03/2013
3	trans-crotonin (CTN)IBA 01/2020 - 01/2018
3	UbiquitinIBA 12/2019 - 08/2017
3	LigandsIBA 01/2019 - 07/2006
3	CD40 Ligand (CD40L)IBA 01/2018 - 07/2005
3	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2018 - 10/2002
3	Transcription Factors (Transcription Factor)IBA 01/2017 - 02/2011
3	Zoledronic Acid (Zometa)FDA Link 11/2014 - 09/2009
3	Antineoplastic Agents (Antineoplastics)IBA 04/2010 - 09/2002
3	Sirolimus (Rapamycin)FDA Link 04/2010 - 12/2004
3	AntibodiesIBA 01/2008 - 01/2004
3	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 10/2007 - 06/2005
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2007 - 07/2006
3	ParaproteinsIBA 08/2005 - 07/2004
3	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2005 - 07/2002
2	venetoclaxIBA 01/2022 - 11/2021
2	idecabtagene vicleucelIBA 01/2022 - 01/2021
2	VaccinesIBA 01/2022 - 07/2013
2	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2018
2	ibrutinibIBA 11/2021 - 08/2012
2	indatuximab ravtansineIBA 11/2021 - 01/2019
2	locked nucleic acidIBA 01/2021 - 03/2016
2	plerixafor FDA Link 11/2019 - 04/2009
2	p21-Activated KinasesIBA 01/2019 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2018 - 10/2003
2	Small Interfering RNA (siRNA)IBA 09/2017 - 07/2005
2	Caspase 3 (Caspase-3)IBA 08/2017 - 12/2009
2	interleukin-21 (interleukin 21)IBA 01/2017 - 01/2016
2	Protein Kinases (Protein Kinase)IBA 01/2017 - 05/2006
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 08/2016 - 09/2004
2	Chemokine CCL20IBA 08/2016 - 01/2014
2	Staphylococcal Protein A (Protein A)IBA 03/2016 - 01/2008

Therapy/Procedure

65	Therapeutics 06/2022 - 08/2002
11	Immunotherapy 01/2021 - 06/2003
9	Drug Therapy (Chemotherapy) 01/2021 - 05/2004
7	Stem Cell Transplantation 01/2022 - 02/2007
4	Transplantation 01/2022 - 03/2007
3	Chemoprevention 12/2010 - 05/2004